砥礪前行，從三大權威指南看T-DXd在HER2陽性晚期胃癌中強勢發展( 四 ) _健康小知識

專家簡介

文章圖片
朱曉東
復旦大學附屬腫瘤醫院腫瘤內科主任醫師，碩士研究生導師
主要從事消化道腫瘤的綜合治療，研究方向為消化道腫瘤耐藥機制及療效預測
主持完成有復旦青年基金、上海市自然科學基金、合作完成數項國家自然基金，并參與完成多個國家重大項目
學術任職：
中國抗癌協會腫瘤靶向治療專業委員會委員
上海市抗癌協會遺傳性消化道腫瘤專業委員會副主任委員
上海市抗癌協會腫瘤生物治療專業委員會常務委員
上海市社會醫療機構協會腫瘤學分會結直腸專委會副主任委員
中國宋慶齡基金會腫瘤醫療及產學研聯盟理事
中國醫藥教育協會腹部腫瘤專業委員會委員
中國抗癌協會腫瘤營養與支持治療專業委員會腫瘤營養化療學組委員
上海市抗癌協會胃腸腫瘤專業委員會委員
上海市抗癌協會癌癥康復與姑息治療專業委員會（CRPC）委員
AnnalsofOncologyExcerptsChinaEdition(GITumors)編委
參考文獻：
[1]SungH,FerlayJ,SiegelRL,etal.GlobalCancerStatistics2020:GLOBOCANEstimatesofIncidenceandMortalityWorldwidefor36Cancersin185Countries.CACancerJClin.2021May;71(3):209-249.
[2]BangYJ,VanCutsemE,FeyereislovaA,etal.TrastuzumabincombinationwithchemotherapyversuschemotherapyalonefortreatmentofHER2-positiveadvancedgastricorgastro-oesophagealjunctioncancer(ToGA):aphase3,open-label,randomisedcontrolledtrial.Lancet.2010Aug28;376(9742):687-97.
[3]中國臨床腫瘤學會指南工作委員會.中國臨床腫瘤學會（CSCO）胃癌診療指南2022[M].北京:人民衛生出版社,2022.
[4]NCCNGastricCancer.2022V2
[5]LordickF,CarneiroF,CascinuS,etal.Gastriccancer:ESMOClinicalPracticeGuidelinefordiagnosis,treatmentandfollow-up.AnnOncol.2022Jul29:S0923-7534(22)01851-8.
[6]LiJ,QinS,XuJ,etal.Randomized,Double-Blind,Placebo-ControlledPhaseIIITrialofApatinibinPatientsWithChemotherapy-RefractoryAdvancedorMetastaticAdenocarcinomaoftheStomachorGastroesophagealJunction.JClinOncol.2016May1;34(13):1448-54.
[7]KangYK,BokuN,SatohT,etal.Nivolumabinpatientswithadvancedgastricorgastro-oesophagealjunctioncancerrefractoryto,orintolerantof,atleasttwopreviouschemotherapyregimens(ONO-4538-12,ATTRACTION-2):arandomised,double-blind,placebo-controlled,phase3trial.Lancet.2017Dec2;390(10111):2461-2471.
[8]ShitaraK,BangYJ,IwasaS,etal;DESTINY-Gastric01Investigators.TrastuzumabDeruxtecaninPreviouslyTreatedHER2-PositiveGastricCancer.NEnglJMed.2020Jun18;382(25):2419-2430.
【砥礪前行，從三大權威指南看T-DXd在HER2陽性晚期胃癌中強勢發展】[9]Trastuzumabderuxtecan(T-DXd;DS-8201)inpatientswithHER2–positiveadvancedgastricorgastroesophagealjunction(GEJ)adenocarcinoma:Finaloverallsurvival(OS)resultsfromarandomized,multicenter,open-label,phase2study(DESTINY-Gastric01).2022ASCOGIAbstract.242.
[10]https://www.daiichisankyo.com/media/press_release/detail/index_4078.html
[11]https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fam-trastuzumab-deruxtecan-nxki-her2-positive-gastric-adenocarcinomas
[12]https://clinicaltrials.gov/
[13]PengZ,LiuT,WeiJ,etal.Efficacyandsafetyofanovelanti-HER2therapeuticantibodyRC48inpatientswithHER2-overexpressing,locallyadvancedormetastaticgastricorgastroesophagealjunctioncancer:asingle-armphaseIIstudy.CancerCommun(Lond).2021Nov;41(11):1173-1182.
[14]Trastuzumabderuxtecan(T-DXd;DS-8201)inpatientswithHER2-low,advancedgastricorgastroesophagealjunction(GEJ)adenocarcinoma:ResultsoftheexploratorycohortsinthephaseII,multicenter,open-labelDESTINY-Gastric01study.2020ESMOMiniOral1422.
[15]PalleJ,RochandA,PernotS,GalloisC,Ta?ebJ,ZaananA.HumanEpidermalGrowthFactorReceptor2(HER2)inAdvancedGastricCancer:CurrentKnowledgeandFuturePerspectives.Drugs.2020Mar;80(4):401-415.